The Vanguard Group, Inc. has recently announced that it has increased stake in DexCom Inc. (NASDAQ:DXCM) by 1.20%. After grabbing 42.06 million shares, the institutional investor is now in possession of 0.5 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 10.89% having worth around $5.08 billion. Moreover, Baillie Gifford & Co. increased its share by 5779.0 to have a control over 18.11 million shares. And SSgA Funds Management, Inc. raised its holdings to 0.16 million shares by acquiring 16.39 million shares or 4.24% of the stake.
DexCom Inc. (DXCM) concluded trading on 11/23/22 at a closing price of $112.92, with 3.53 million shares of worth about $398.51 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 60.56% during that period and on Wednesday the price saw a gain of about 1.72%. Currently the company’s common shares owned by public are about 389.80M shares, out of which, 382.65M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 20 analysts are covering the DXCM stock and their offered price forecasts bring an average price target of $122.33. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $140.00 and could fall to a lowest price of $100.00. The stock’s current price level is 7.13% above of average price target set by the analysts, while a rise to estimated low would result in loss of -12.92% for the stock. However, touching the estimated high of $140.00 would mean a gain of 19.34% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 159 times over the past 12 months. They bought 159,934 shares in 40 of the transactions. In 119 selling transactions, insiders dumped 101,932 shares.
Vanguard Total Stock Market Index, Vanguard Mid Cap Index Fund, and Vanguard 500 Index Fund are the top 3 mutual funds which are holding stakes in DexCom Inc. Vanguard Total Stock Market Index is currently holding 11.79 million shares of worth totaling $1.42 billion. The company recently came buying 66089.0 shares which brought its stake up to 3.05% of the company’s outstanding shares. Vanguard Mid Cap Index Fund bought 0.11 million shares, after which its hold over company’s outstanding shares expand to 2.37%, leaving 9.17 million shares with the mutual fund that have a worth of about $1.11 billion. Vanguard 500 Index Fund, after buying 8.98 million shares, have now control over 2.33% of the stake in the company. It holds 86424.0 shares of worth $1.09 billion.
DexCom Inc. (NASDAQ: DXCM) started trading at $111.67, above $0.66 from concluding price of the previous day. However, the stock later moved at a day high price of 113.32, or with a gain of 1.72%. Stock saw a price change of -1.71% in past 5 days and over the past one month there was a price change of 11.86%. Year-to-date (YTD), DXCM shares are showing a performance of -15.88% which decreased to -23.44% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $66.89 but also hit the highest price of $154.51 during that period. The average intraday trading volume for DexCom Inc. shares is 2.77 million. The stock is currently trading -1.03% below its 20-day simple moving average (SMA20), while that difference is up 12.34% for SMA50 and it goes to 18.82% higher than SMA200.
The Vanguard Group, Inc. acquired 42.06 million shares of DexCom Inc. having value of about $5.08 billion. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 0.5 million shares in the company valued at close to $56413025.28, or have control over 1.20% stake in the company. DexCom Inc. (NASDAQ: DXCM) currently have 389.80M outstanding shares and institutions hold larger chunk of about 98.40% of that. Holding of mutual funds in the company is about 35.53% while other institutional holders and individual stake holders have control over 61.74% and 2.64% of the stake respectively.
The stock has a current market capitalization of $43.20B and its 3Y-monthly beta is at 1.16. PE ratio of stock for trailing 12 months is 211.07, while it has posted earnings per share of $0.54 in the same period. Its PEG reads 6.42 and has Quick Ratio of 3.40 while making debt-to-equity ratio of 1.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DXCM, volatility over the week remained 2.43% while standing at 3.87% over the month.
Analysts are in expectations that DexCom Inc. (DXCM) stock would likely to be making an EPS of $0.3 in the current quarter, while forecast for next quarter EPS is $0.18 and it is $1.1 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.25 which is $0.34 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.17 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -69.50% while it is estimated to increase by 35.96% in next year. EPS is likely to grow at an annualized rate of 32.90% for next 5-years, compared to annual growth of 31.70% made by the stock over the past 5-years.
Analysts at 20 brokerage firms have issued recommendations for the DexCom Inc. (DXCM)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.60. Out of those 20 Wall Street analysts, 13 recommended a “Buy” rating, while 3 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Barclays on October 18, 2022 offering an Equal weight rating for the stock and assigned a target price of $103 to it. Coverage by Jefferies stated DexCom Inc. (DXCM) stock as a Buy in their note to investors on October 12, 2022, suggesting a price target of $125 for the stock. On July 15, 2022, Bernstein Initiated their recommendations, while on March 02, 2022, BofA Securities Resumed their ratings for the stock with a price target of $500. Stock get a Buy rating from BTIG Research on February 03, 2022.